Ligence

Executive Summary

Ligence is a Swiss medical AI company developing vendor-neutral, web-based software for automating the analysis and reporting of 2D transthoracic echocardiograms (TTE). Its flagship product, Ligence Heart™, leverages artificial intelligence to segment heart structures and automate measurements, reducing reporting time for cardiologists while improving consistency. The software is both FDA-cleared and CE-marked, integrates with hospital IT systems, and supports major cardiac imaging guidelines. Founded in 2019 and headquartered in Zurich, Ligence is privately held with no disclosed funding or valuation. Despite limited public information, the company has achieved regulatory clearances in both the US and Europe, positioning it for commercial growth in the echocardiography AI market. Its vendor-neutral approach and web-based platform offer a competitive advantage by facilitating broad hospital adoption without hardware dependencies. As cardiovascular imaging volumes rise, Ligence is well-placed to address workflow inefficiencies; however, execution risk remains given its early commercial stage and the competitive landscape from larger AI imaging firms.

Upcoming Catalysts (preview)

• Q3 2026Expansion into the US market through hospital partnerships or OEM agreements60% success
• Q4 2026Publication of validation study results in peer-reviewed journal70% success
• Q2 2026Release of upgraded product version with additional automated measurements or 3D echo support50% success